Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633210 | 0.89 | SMN1; SMN2 (0.39) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL5630149 | 0.88 | HSD17B10 (0.40) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| Trifluoroacetic Acid SCHEMBL5632063 | 0.87 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| Trifluoroacetic Acid SCHEMBL5632073 | 0.87 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL4976988 | 0.85 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL4976998 | 0.85 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL5631804 | 0.84 | HPGD (0.46) | MEN1KMT2AMAPTCYP1A2CYP3A4 | |
| SCHEMBL5631779 | 0.84 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL5633253 | 0.84 | CYP1A2 (0.42) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL15093591 | 0.83 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971583-B1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8951536-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-02-10 | — | — | US | disclosed |
| US-20130177590-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-8450351-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177590-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | MEN1 1163/4885KMT2A 545/4885SMN1; SMN2 3175/4885 |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, HNMT | MEN1 1163/4885KMT2A 545/4885SMN1; SMN2 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.